Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158896 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease
A Phase 1 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03158896 is a Phase 1 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 24 participants.
The verdict
NCT03158896, a Phase 1 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host Disease (aGVHD). The first 5 participants enrolled in the study will receive a lower dose of MSCTC-0010. If none of the first 5 participants have treatment-related serious adverse events (TRSAEs) for 42 days, then the next 5 participants will receive a slightly higher dose of MSCTC-0010.
Interventions
- BIOLOGICAL MSCTC-0010 Dose Escalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-07-09 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03158896
The ClinicalTrials.gov registry entry for NCT03158896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSCTC-0010 Dose Escalation is the first listed.
NCT03158896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03158896 about?
NCT03158896 is a clinical study titled "Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease". This study evaluates the safety and effectiveness of two different doses of umbilical cord derived, ex-vivo cultured and expanded Wharton's jelly mesenchymal stem cells (MSCTC-0010) in the treatment of acute Graft versus Host Disease (aGVHD). The first 5 participants enrolled in the study will recei...
What is the current status of trial NCT03158896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-07-09. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT03158896?
The interventions under investigation include: MSCTC-0010 Dose Escalation (BIOLOGICAL).
Who is sponsoring clinical trial NCT03158896?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.